Pirfenidone improves survival in IPF: results from a real-life study
Abstract Background Pirfenidone is an antifibrotic compound approved for the treatment of idiopathic pulmonary fibrosis (IPF). We present our real-world experience in terms of Pirfenidone’s effect on mortality and adverse events profile outside the restrictions of a clinical trial. Methods This is a...
Na minha lista:
| Principais autores: | , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BMC
2018-11-01
|
| coleção: | BMC Pulmonary Medicine |
| Assuntos: | |
| Acesso em linha: | http://link.springer.com/article/10.1186/s12890-018-0736-z |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|
